Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients

J Infect Dis. 1992 Oct;166(4):723-30. doi: 10.1093/infdis/166.4.723.

Abstract

Peripheral blood mononuclear cells from 12 asymptomatic patients infected with immunodeficiency virus (HIV) and 4 patients with AIDS were analyzed before and during therapy with zidovudine for T helper cell (Th) function. Th function improved by more than fourfold to one or more of three stimuli tested in 9 (75%) of 12 asymptomatic patients on zidovudine therapy and in 3 of 4 patients with AIDS. Only 6 (7.4%) of 80 untreated HIV-infected control patients showed spontaneous improvement in Th function (P less than 10(-6)). Improved Th function was detected as early as 5 weeks into therapy in 6 patients and continued to be evident for greater than 1 year after start of therapy in 6 patients and for greater than 2 years in 2 patients. No correlation was observed between improved Th function and changes in CD4+ or CD8+ cell numbers or in levels of serum HIV p24 antigen or beta 2-microglobulin. These results suggest inclusion of in vitro Th function as a useful marker in determining the efficacy of antiretroviral drug therapy of HIV-infected patients.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / immunology
  • CD4 Antigens / analysis
  • CD8 Antigens / analysis
  • Drug Administration Schedule
  • HIV Core Protein p24 / analysis
  • Humans
  • Neutrophils / drug effects
  • T-Lymphocytes, Helper-Inducer / drug effects*
  • T-Lymphocytes, Helper-Inducer / physiology
  • Zidovudine / therapeutic use*
  • beta 2-Microglobulin / analysis

Substances

  • CD4 Antigens
  • CD8 Antigens
  • HIV Core Protein p24
  • beta 2-Microglobulin
  • Zidovudine